GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (MEX:BIIB) » Definitions » Cyclically Adjusted Price-to-FCF

Biogen (MEX:BIIB) Cyclically Adjusted Price-to-FCF : 5.20 (As of Jul. 01, 2025)


View and export this data going back to 2013. Start your Free Trial

What is Biogen Cyclically Adjusted Price-to-FCF?

As of today (2025-07-01), Biogen's current share price is MXN2397.99. Biogen's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 was MXN460.93. Biogen's Cyclically Adjusted Price-to-FCF for today is 5.20.

The historical rank and industry rank for Biogen's Cyclically Adjusted Price-to-FCF or its related term are showing as below:

MEX:BIIB' s Cyclically Adjusted Price-to-FCF Range Over the Past 10 Years
Min: 5.21   Med: 19.54   Max: 79.47
Current: 5.71

During the past years, Biogen's highest Cyclically Adjusted Price-to-FCF was 79.47. The lowest was 5.21. And the median was 19.54.

MEX:BIIB's Cyclically Adjusted Price-to-FCF is ranked better than
94.46% of 325 companies
in the Drug Manufacturers industry
Industry Median: 31.18 vs MEX:BIIB: 5.71

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Biogen's adjusted free cash flow per share data for the three months ended in Mar. 2025 was MXN29.613. Add all the adjusted free cash flow per share for the past 10 years together and divide 10 will get our Cyclically Adjusted FCF per Share, which is MXN460.93 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Biogen Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Biogen's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Cyclically Adjusted Price-to-FCF Chart

Biogen Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 15.94 13.36 14.55 12.23 6.94

Biogen Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.89 10.62 8.82 6.94 6.19

Competitive Comparison of Biogen's Cyclically Adjusted Price-to-FCF

For the Drug Manufacturers - General subindustry, Biogen's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biogen's Cyclically Adjusted Price-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Biogen's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Biogen's Cyclically Adjusted Price-to-FCF falls into.


;
;

Biogen Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Biogen's Cyclically Adjusted Price-to-FCF for today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/ Cyclically Adjusted FCF per Share
=2397.99/460.93
=5.20

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biogen's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Biogen's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2025 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=29.613/134.9266*134.9266
=29.613

Current CPI (Mar. 2025) = 134.9266.

Biogen Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201506 61.070 100.684 81.840
201509 47.941 100.392 64.433
201512 81.690 99.792 110.451
201603 67.529 100.470 90.688
201606 75.019 101.688 99.540
201609 62.624 101.861 82.953
201612 132.880 101.863 176.012
201703 -72.386 102.862 -94.950
201706 72.100 103.349 94.130
201709 115.597 104.136 149.777
201712 113.216 104.011 146.867
201803 107.478 105.290 137.731
201806 79.100 106.317 100.386
201809 143.155 106.507 181.354
201812 163.739 105.998 208.426
201903 131.197 107.251 165.053
201906 179.286 108.070 223.842
201909 171.998 108.329 214.227
201912 179.472 108.420 223.349
202003 163.310 108.902 202.338
202006 264.461 108.767 328.066
202009 154.159 109.815 189.411
202012 -60.425 109.897 -74.187
202103 90.783 111.754 109.607
202106 153.227 114.631 180.355
202109 102.865 115.734 119.923
202112 107.062 117.630 122.805
202203 14.016 121.301 15.590
202206 96.008 125.017 103.618
202209 83.613 125.227 90.090
202212 -35.184 125.222 -37.911
202303 47.632 127.348 50.467
202306 47.131 128.729 49.400
202309 60.726 129.860 63.096
202312 -6.131 129.419 -6.392
202403 49.175 131.776 50.351
202406 73.230 132.554 74.541
202409 108.573 133.029 110.122
202412 99.290 133.157 100.609
202503 29.613 134.927 29.613

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Biogen  (MEX:BIIB) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Biogen Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Biogen's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Biogen Business Description

Industry
Address
225 Binney Street, Cambridge, MA, USA, 02142
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.